Aytu BioPharma - AYTU Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aytu BioPharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AYTU shares.
View AYTU analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 12-month price targets for Aytu BioPharma's shares. Their AYTU share price forecasts range from $5.00 to $6.00. On average, they anticipate the company's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 1,883.4% from the stock's current price.
View analysts price targets for AYTU or view top-rated stocks among Wall Street analysts.

Aytu BioPharma's stock was trading at $1.35 at the beginning of the year. Since then, AYTU stock has decreased by 79.5% and is now trading at $0.2773.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, September 26th 2022.
View our AYTU earnings forecast.

Aytu BioPharma, Inc. (NASDAQ:AYTU) issued its earnings results on Monday, November, 15th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.60. The firm had revenue of $21.90 million for the quarter. Aytu BioPharma had a negative trailing twelve-month return on equity of 41.97% and a negative net margin of 120.24%. During the same quarter in the prior year, the company earned ($0.40) earnings per share.

Aytu BioPharma shares reverse split on the morning of Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioPharma investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), iBio (IBIO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and SCYNEXIS (SCYX).

Aytu BioPharma trades on the NASDAQ under the ticker symbol "AYTU."

Aytu BioPharma's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.74%), Millennium Management LLC (0.45%), Prudential Financial Inc. (0.10%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armistice Capital Master Fund, Armistice Capital, Llc and Joshua R Disbrow.
View institutional ownership trends.

Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AYTU stock can currently be purchased for approximately $0.28.

Aytu BioPharma (NASDAQ:AYTU) has a market capitalization of $10.86 million and generates $65.63 million in revenue each year. The company earns $-58,290,000.00 in net income (profit) each year or ($4.13) on an earnings per share basis.

The company employs 175 workers across the globe.

Aytu BioPharma's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The official website for the company is aytubio.com. The company can be reached via phone at (720) 437-6580 or via email at james@haydenir.com.